Skip to content

Welcome to Discover Pharma! Today is : October 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

CNS

  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Ariadne Bio launches with Parkinson’s apathy drug candidate

    Ariadne Bio has launched with funding from The Michael J [...]

    September 18, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    NIH funds expanded access programme for Neurizon’s ALS therapy

    A US National Institutes of Health grant will fund an [...]

    September 16, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    CAMP4 wins Australian clearance to begin Phase 1/2 trial of SYNGAP1 therapy

    CAMP4 Therapeutics has received Australian regulatory and ethics clearance to [...]

    July 27, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    CHMP recommends approval of NEZGLYAL for rare neurodegenerative disease

    The EMA’s CHMP has recommended approval of NEZGLYAL for boys [...]

    July 24, 2026
  • Biotech & Pharma Business,Central Nervous System

    Alto Neuroscience raises $100M to expand Phase 3 treatment-resistant depression programme

    Alto Neuroscience has raised $100 million through an underwritten registered [...]

    July 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data

    Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

    July 14, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation

    Vect-Horus and Servier partner on targeted oligonucleotide therapies for rare CNS diseases

    Vect-Horus has entered a research collaboration and exclusive licence option [...]

    July 3, 2026
  • Central Nervous System,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA authorises Emalex Biosciences’ Expanded Access Program for Tourette syndrome drug

    Emalex Biosciences has received FDA authorisation for an Expanded Access [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia

    Celon Pharma S.A. has received FDA clearance to advance its [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • E2 secures FDA clearance for pulmonary embolism thrombectomy system
    Categories: Clinical & Regulatory, Medical devices
  • Carterra and AstraZeneca target AI-driven drug discovery
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Research & Development
  • Biopharma dealmaking outlook improves despite investor caution
    Categories: Biotech & Pharma Business, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top